Grady Mike, Holt Elizabeth, Cameron Hilary, Edelman Steven
LifeScan Scotland Ltd, Beechwood Park North, Inverness, IV2 3ED, UK.
LifeScan Global Corporation, 20 Valley Stream Parkway, Malvern, PA, 19355, USA.
Sci Rep. 2025 Mar 14;15(1):8871. doi: 10.1038/s41598-025-93605-1.
The increasing prevalence of metabolic syndrome and type 2 diabetes places a burden on healthcare systems, necessitating cost-effective, engaging and accessible interventions to address the underlying behavioral and lifestyle drivers. Our study evaluated combining Bluetooth connected OneTouch blood glucose meters (BGM) and the OneTouch Reveal mobile app with one of four digital therapeutic apps. Each group was independent, with people with type 2 diabetes (PwT2D) themselves choosing their therapeutic intervention, to better reflect real-world use. Our 3-month decentralized study screened 912 subjects, with 612 returning mail-in A1cs, providing 191 subjects (Noom = 68, Fitbit = 31, Cecelia Health = 47, Welldoc = 45) who met all inclusion criteria, including entry A1c 7.5 to 12.0%. The primary endpoint of A1c change showed improvement in the overall group by - 0.77% (95% CI - 0.98 to - 0.56, n = 141) after 3-months, Noom - 1.03% (CI - 1.4 to - 0.61, n = 49), Fitbit - 0.56% (CI - 1.0 to - 0.11, n = 24), Cecelia Health - 0.76% (CI - 1.2 to - 0.36, n = 36), Welldoc - 0.55% (CI - 0.94 to - 0.17, n = 32). In terms of secondary endpoints, more than half (56%) of these PwT2D lowered A1c by ≥ 0.5% and more than a third (36%) lowered A1c by ≥ 1.0%, with similar improvements across each of the four independent groups. Our real-world approach shows the potential for connected BGMs and widely accessible digital therapeutics to contribute to improvements in glycemic outcomes.
代谢综合征和2型糖尿病的患病率不断上升，给医疗系统带来了负担，因此需要采取具有成本效益、引人入胜且易于获得的干预措施来解决潜在的行为和生活方式驱动因素。我们的研究评估了将蓝牙连接的OneTouch血糖仪（BGM）和OneTouch Reveal移动应用程序与四款数字治疗应用程序之一相结合的效果。每个组都是独立的，2型糖尿病患者（PwT2D）自己选择治疗干预措施，以更好地反映实际使用情况。我们为期3个月的分散式研究筛选了912名受试者，其中612人返回了邮寄的糖化血红蛋白（A1c）检测结果，共有191名受试者（Noom组 = 68人，Fitbit组 = 31人，Cecelia Health组 = 47人，Welldoc组 = 45人）符合所有纳入标准，包括初始A1c在7.5%至12.0%之间。糖化血红蛋白变化的主要终点显示，3个月后总体组改善了 - 0.77%（95%置信区间 - 0.98至 - 0.56，n = 141），Noom组为 - 1.03%（置信区间 - 1.4至 - 0.61，n = 49），Fitbit组为 - 0.56%（置信区间 - 1.0至 - 0.11，n = 24），Cecelia Health组为 - 0.76%（置信区间 - 1.2至 - 0.36，n = 36），Welldoc组为 - 0.55%（置信区间 - 0.94至 - 0.17，n = 32）。在次要终点方面，超过一半（56%）的这些2型糖尿病患者糖化血红蛋白降低了≥ 0.5%，超过三分之一（36%）降低了≥ 1.0%，四个独立组中的每一组都有类似的改善。我们的实际应用方法表明，联网的血糖仪和广泛可用的数字治疗方法有可能有助于改善血糖结果。
